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ABSTRACT 
Oral drug delivery system represents one of the frontier area of controlled drug delivery system. Floating drug delivery system 
belongs to oral controlled drug delivery system group, which is capable of floating in the stomach for prolong period of time. The 
objective of the present research work is to provide a gastroretentive system for sustained release of therapeutically active agent, 
cefuroxime axetil in upper part of gastro-intestinal tract in the form of floating tablet. Cefuroxime axetil, an oral prodrug shows a 
bioavailablity of 30% to 40% when taken on fasting and 5% to 60% whentaken after food. The cefuroxim axetil esterase can 
hydrolyze cefuroximeaxetil to the nonabsorbable cefuroxim in the gut lumen and is therefore, suspected as a possible cause of 
incomplete bioavailability. Which suggests an absorption mechanism through the mucosa with limited capacity. Cefuroxime axetil 
had saturation kinetics that could be overcome by slow release of drug from the formulation, by incorporating cefuroxime axetil in 
sustained drug delivery system. 
Keywords: Floating drug delivery system, Cefuroxime axetil, Gastro-intestinal tract  
 
 
Article Info 
Received 14 Nov 2016; Review Completed 14 Dec 2016; Accepted 27 Dec 2016, Available online 15 Jan 2017 
Cite this article as: 
Gurjar GS, Bhowmick M, Rathi V, Rathi J, Design and evaluation of extended release cefuroxime axetil floating tablets with improved G.I. 
absorption, Journal of Drug Delivery and Therapeutics. 2017; 7(1):49-59, DOI: http://dx.doi.org/10.22270/jddt.v7i1.1352  
*Address for Correspondence  
Gaurav Singh Gurjar, NRI Institute of Pharmaceutical Sciences, Bhopal, India, Email: gauravgurjarsrcp@gmail.com 
 
 
INTRODUCTION 
FDDS is also called Hydrodynamic Balance System 
(HBS) system, is an effective technology to prolong the 
gastric retention time in order to improve the 
bioavailability of drug. FDDS that float immediately 
upon contact with gastric fluid present promising 
approaches for increasing the bioavailability of drugs 
with absorption windows in the upper intestine. 
An attempt has been made to systemically investigate 
the contribution of several formulation variables on the 
physico-chemical properties, in vitro drug release and 
floating properties of floating drug delivery system for 
absorption window limited drug with short half-life 
like, Cefuroxime axetil. Cefuroxime axetil (CA) is 
abroad spectrum ß-lactamase cephalosporin that has 
well defined pharmacokinetics after intramuscular and 
intravenous administration in the form of sodium salt. 
In humans, gastrointestinal absorption of cefuroxime is 
negligible. Cefuroxime axetil had higher absorption in 
the proximal region of GI tract and poor absorption, as 
well as antibiotic associated colitis, when a large 
amount of drug entered the colon suggest it is an ideal 
candidate for a gastroretentive drug delivery system 
that will prolong the gastric residence time of the 
dosage form, giving prolonged drug release in the 
upper GI tract, where absorption of cefuroxime is well 
defined.
1-6
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MATERIAL AND METHODS:  
Materials: 
The drug Cefuroxime axetil was received as a gift 
sample from Zeel Pharma, Mumbai, India. Hydroxy 
Propyl Methyl Cellulose- K4M, Eudragit RL-100 and 
Hydroxy Propyl Cellulose were obtained from 
Colorcon asia Pvt. Ltd (Goa, India), ,  Ethyl cellulose, 
Micro Crystalline Cellulose. Polyvinyl pylorridone, 
Sodium Bicarbonate, Citric acid, Iso Propyl Alcohol, 
Magnesium Stearate and lactose were obtained from 
SD Fine chemicals Mumbai,   All the solvent used were 
of analytical grade. 
Methods: 
Preformulation studies 
7-12
: 
(a) Organoleptic properties  
The sample of cefuroxime axetil  was studied for 
organoleptic characters such as color, odor and 
appearance. 
(b) Melting point 
Melting point was determined by open capillary 
method using melting point apparatus. 
(c) FTIR Spectroscopy 
The FTIR spectrum of  Cefuroxime axetil  was 
recorded using FTIR spectrophotometer  (Shimadzu 
8400S) using KBr pellet technique.  The peaks are is 
shown in fig  
(d) UV spectroscopy (Determination of λ Max) 
Stock solution (100 μg/ml) of cefuroxime axetil was 
prepared in 0.1N HCL.  This solution was appropriately 
diluted with 0.1N HCL to obtain a concentration of 30  
µg/ml. The solution was kept in a fused silica cuvette 
10 mm. The UV spectrum was recorded in the range of 
200-400 nm on UV Visible Spectrophotometer 
(Shimadzu 1600) 
Calibration curve for cefuroxime axetil 
100 mg cefuroxime axetil was accurately weighted 
&transferred to 100ml volumetric  flask.  It was then 
dissolved in  0.1NHCL    and sonicated for 10 min 
&diluted to volume   with 0.1N hcl to give stock 
solution containing 1000 mg/ml. This solution was 
appropriately diluted with 0.1N HCL to obtain a 
concentration  of 5,10,15,20,25,and 30 µg/ml.  The 
above solutions were analyzed by U.  V. 
Spectrophotometer at 280 nm. All the dilutions were 
made using 0.1N HCL    was used as a blank during 
spectrometric analysis.  
(e) Differential scanning calorimetry studies 
Thermal analysis was performed using  (DSC60 
Shimadzu)  system with a differential   scanning 
calorimeter equipped with a computerized data station. 
All samples were weighed and heated at a scanning rate 
of 10°C/min between 30 and 300°C and 40 ml/min of 
nitrogen flow. The differential scanning calorimetry 
analysis gives an idea about the interaction of various 
materials at different temperature. It also allows us to 
study the possible degradation pathway of the 
materials. 
(f) Determination of solubility 
Cefuroxime Axetil solubility study was carried out 
using saturation method. 
(g) Drug Excipients Interaction 
The possibility of any interaction between the drug and 
the carriers was detected by Fourier Transform Infrared 
(FTIR) spectroscopy and Differential Scanning 
Calorimetry (DSC). 
Fabrication of Tablets 
13-19
:  
Each floating tablets containing 250mg cefuroxime 
axetil  were  prepared by a conventional wet 
granulation method,  employing sodium bicarbonate, 
citric acid as gas generating agent and different 
polymers in each formulation. Cefuroxime Axetil, 
Lactose and polymers were passed from sieve of # 40 
and mixed for 10 min. Gas generating agent was then 
passed through sieve of # 60 added to the above 
mixture. Binding solution of polyvinyl pyloridone was 
Prepared in Isopropyl alcohol. Dry at room temperature 
and pass from sieve of # 40. Magnesium stearate was 
passed through sieve of # 60 and added to the above 
mixture. The whole bulk of granules were then mixed 
thoroughly for 15 min. The granules were then 
compressed to form a tablet. 
 
Table 1: Table showing the formulation codes and polymer content 
  
Formulation Code F1 F2 F3 F4 F5 F6 F7 
DRUG (mg) 250 250 250 250 250 250 250 
HPMC K4M (mg) 60 -- -- -- 30 30 30 
ETHYL CELLULOSE (mg) -- 60 -- -- 30 -- -- 
EUDRAGIT-RL-100 (mg) -- -- 60 -- -- 30 -- 
HPC (mg) -- -- -- 60 -- --- 30 
NaHCO3 (mg) 100 100 100 100 100 100 100 
CITRIC ACID (mg) 30 30 30 30 30 30 30 
MG. STEARATE (mg) 10 10 10 10 10 10 10 
LACTOSE (mg) 50 50 50 50 50 50 50 
Total (mg) 500 500 500 500 500 500 500 
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Evaluation of Granule Properties 
20-28
: 
The flow properties of granules were characterized in 
terms of angle of repose, Carr’s index and Hausner's 
ratio.The bulk density and tapped density were 
determined and from this data Carr's index and 
Hausner's ratio were calculated. 
(a) Bulk density: 
Both untapped bulk density, ρu (often called loose or 
aerated bulk density) and tapped bulk density, ρb were 
determined. A amount of powder blend was introduced 
in a 10 ml measuring cylinder up to 9 ml volume.Then 
the weight of powder blend was determined by 
substracting the weight of empty measuring cylinder 
from final weight of measuring cylinder. The cylinder 
was allowed to fall onto a hard surface from a height of 
2.5 cm at 2 sec intervals. The tapping was continued till 
no volume change was noted. ρu and ρb were determined 
by following formulas; 
    
          
                                                                                     (1) 
 
                                                               (2)                 
                                                                                   
(b) Carr’s Compressibility Index: 
An important measure that can be obtained from bulk 
density determinations is the percent compressibility C, 
which is defined as follows 
 
(3)                                                                                           
(c) Hausner ratio: A similar index has been defined by 
Hausner. 
                                                                           (4)                                         
                                                                                     
(d) Angle of repose: 
The angle of repose of the powder blend was determined 
by using funnel method. The accurately weighed 
powder were taken in a funnel. The height of the funnel 
was adjusted in such a way that the tip of the funnel just 
touched the apex of the heap of the powder. The 
diameter of the powder cone was measured and angle of 
repose was calculated by using the equation 
 
Where h and r are the height and radius of the powder 
cone.  
Average values are shown in Table  
Table 2: Standard values of angle of repose (θ). 
Evaluation of tablets 
20-25
: 
 (a) Tablet thickness and size 
 Thickness and diameter of tablets were important for 
uniformity of tablet size. Thickness and diameter was 
measured using Vernier callipers.  
 (b) Tablet hardness 
The resistance of tablets to shipping or breakage, under 
conditions of storage, transportation and handling before 
usage depends on its hardness. The hardness of tablet of 
each formulation was measured by Monsanto hardness 
tester. The hardness was measured in terms of kg/cm
2
. 
(c) Friability 
Friability is the measure of tablet strength. Roche type 
friabilator was used for testing the friability using the 
following procedure. Twenty tablets were weighed 
accurately and placed in the tumbling apparatus that 
revolves at 25 rpm dropping the tablets through a 
distance of six inches with each revolution. After 4 min., 
the tablets were weighed and the percentage loss in 
tablet weight was determined. 
                Initial wt. of tablets – Final wt. of tablets 
% loss                                                                    x100 
Initial wt. of tablets 
(d) Uniformity of weight  
Twenty tablets were selected at random and the average 
weight was calculated. Weight variation was calculated 
and was compared with I. P. standards. 
 (e) Drug content  
Five tablets were weighed and powdered. The quantity 
equivalent to 5oo mg of cefuroxime axetil was weighed 
accurately and taken in 500-ml volumetric flask. 200 
milliliters of 0.1N HCl was added, sonicated for 5 min, 
made up to 500 ml with 0.1 N HCl, and filtered. From 
above solution further dilution was made and the drug 
concentration was determined at 278 nm by using UV 
spectrophotometer. Drug content was calculated by 
using absorbance at wavelength 280 nm. The results 
obtained were compared with I. P. standards. 
(f) Matrix integrity 
Matrix integrity was observed throughout in vitro 
dissolution studies and the swollen mass of the tablets 
remain intact or not was checked.  
(g)Buoyancy lag time  
This test was performed in beaker containing 200 ml pH 
1.2 buffer as a testing medium maintained at 37°C. The 
time required for the tablet to rise to the surface and 
float was determined as buoyancy lag time. 
(h) The duration of Buoyancy time  
The time, for which the tablet constantly floats on the 
surface of the medium, duration of buoyancy, was 
measured. The duration of buoyancy was determined 
using a USP dissolution apparatus Type II containing 
900 mL of 0.1 N HCL at 50 rpm.  
Flowability            Angle of repose 
Excellent <25 
Good 25-30 
Passable* 30-40 
Poor 37-45 
Very poor >45 
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(i) Swelling behaviour  
The swelling index of tablet was determined in 900 ml 
Glycin (pH 3) using USP dissolution apparatus Type II 
at 75 rpm. The medium was maintained at 37±0.5 ◦C 
throughout the study. After a selected time intervals, the 
tablet was withdrawn, blotted to remove excess water 
and weighed. Swelling characteristics of the tablet was 
expressed in terms of swelling index  
 
  
where W0 is the initial weight of tablet, & Wt is the 
weight of tablet at time t. 
(j) In vitro dissolution studies  
The release rate of cefuroxime axetil from matrix tablets 
was determined using USP dissolution testing apparatus 
II (Paddle type). The dissolution test was performed 
using 900 ml of 0.1N HCL, at 37 ± 0.5°C and 50 rpm. A 
5 ml sample solution was withdrawn from the 
dissolution apparatus for 30 min, 1 hr and there after 
every hour for 12 hrs. Samples were replaced by its 
equivalent volume of dissolution medium. The samples 
were filtered through Whatman filter paper and 
solutions were analyzed at 280 nm by UV 
Spectrophotometer (Libindia Disso-2000). Cumulative 
percentage drug release was calculated. 
Drug release kinetics
 
Dissolution data of above two methods was fitted in 
Zero order, First order and Higuchi equations.  
The mechanism of drug release was determined by 
using Korsmayer Peppas equation. 
Zero-Order Kinetics:
 
Zero order as cumulative amount of drug released vs 
time, 
C = K0 t 
Where K0 is the zero-order rate constant expressed in 
units of concentration/time and t is the time in hours. A 
graph of concentration vs time would yield a straight 
line with a slope equal to K0 and intercept the origin of 
the axes.  
First order kinetics: 
First order as log cumulative percentage of drug 
remaining vs time,  
     L o g C = L o g C o − k t / 2.303 
Where C0 is the initial concentration of drug, k is the 
first order constant, and t is the time.  
Higuchi Model: 
Higuchi’s model as cumulative percentage of drug 
released vs square root of time  
Q = K t 
1 / 2
 
Where K is the constant reflecting the design variables 
of the system and t is the time in hours. Hence, drug 
release rate is proportional to the reciprocal of the 
square root of time.  
Korsmayer Peppas equations:
 
To evaluate the mechanism of drug release from 
Disulfiram implant, data for the first 60% of drug 
release were plotted in Korsmeyer et al’s equation log 
cumulative percentage of drug released vs log time, and 
the exponent n was calculated through the slope of the 
straight line.  
M t / M ∞ = K t n 
where Mt/M∞ is the fractional solute release, t is the 
release time, K is a kinetic constant characteristic of the 
drug/polymer system, and n is an exponent that 
characterizes the mechanism of release of tracers. For 
cylindrical matrix tablets, if the exponent n = 0.45, then 
the drug release mechanism is Fickian diffusion, and if 
0.45 < n < 0.89, then it is non-Fickian or anomalous 
diffusion. An exponent value of 0.89 is indicative of 
Case-II Transport or typical zero-order release.  
RESULTS AND DISCUSSION 
PREFORMULATION STUDIES 
Characterization of cefuroxime axetil 
A. Organoleptic properties  
The sample of cefuroxime axetil was found to be a 
yellowish white to light white crystalline powder. It has 
characteristic odor and bitter test. 
B. Melting point 
The melting point of cefuroxime axetil was found to be 
in the range of 218-225°C 
C. FTIR spectroscopy 
The FTIR spectrum is shown in Figure 1 and 
interpretation of FTIR spectra is given in Table 3.FTIR 
spectrum of cefuroxime axetil showed all the peaks 
corresponding to the functional groups present in the 
structure of cefuroxime axetil. 
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Figure 1:  FTIR spectrum of cefuroxime axetil 
 
Table 3: Interpretation of FTIR spectrum of Cefuroxime Axetil 
 
 
 
 
 
 
 
 
D. UV spectroscopy (Determination of λmax)
 
Wavelength of maximum absorbance (max) of 
cefuroxime axetil was found to be 280 nm in 0.1N 
HCL. The UV spectrum is shown in Figure 2 
 
Figure 2: UV spectrum of Cefuroxime Axetil 
 
Calibration curve for cefuroxime axetil 
The calibration curve for cefuroxime axetill in 0.1N 
HCL is shown in Figure 3 . The graph of absorbance 
vs. concentration for cefuroxime axetil was found to be 
linear in the concentration range of 5-30 μg/ml at 280 
nm. The r
2 
of the calibration curve was found to be 
0.997 
 
Figure 3: Calibration curve for cefuroxime axetil
 
 
 
 
 
 
y = 0.036x + 0.065 
R² = 0.997 
0 
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1 
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CONC.(µg/ml) 
ABS. 
Linear (ABS.) 
S.N. Peak observed (cm
-1
) Interpretation 
1.  2937 C-H stretching(aliphatic) 
2.  2984 C-H stretching(aromatic) 
3.  3330 N-H stretching 
4.  1618 N-H bending 
5.  1074, 1099 C-O stretching 
6.  1761 C=O stretching 
7.  674 C-S-C stretching 
8.  1274 C-N stretching 
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E. Differential Scanning Calorimetry study 
Differential Scanning Calorimetry studies indicated a sharp endothermic peak at 210°C for pure cefuroxime axetil.  
 
Figure 4: DSC graph of cefuroxime axetil 
 
G. Solubility: 
Cefuroxime axetil soluble in acetone, ethanol, and in 
chloroform. It is slightly soluble In Dehydrate Alcohol. 
Cefuroxime axetil insoluble in water. 
H. Drug Excipients Interaction 
FTIR is called as fingerprint technique and is widely 
used in identification of drugs and excipients. The FTIR 
spectra of drug was compared with FTIR spectra of drug 
and excipients mixture. There was no significant change 
in the position of this peak in the FTIR spectra of drug 
and excipients mixture. So it can be concluded that the 
excipients and drug do not interact with each other. 
DSC thermograms of drug and polymer samples showed 
the peaks at 215.60
o
C and 195.30
o
C respectively. These 
are the temperatures corresponding to the melting points 
of Cefuroxime axetil and polymers respectively. There 
was no significant change in the position of this peak in 
the thermograms of drug and excipients mixture. So it 
can be concluded that the excipients and drug do not 
interact with each other. 
 
 
Figure 5: Comparative study of drug and excipients by FTIR spectrum (A)Drug+HPMC K4M (B) Drug+ethyl 
cellulose(C) Drug+Eudragit RL-100(D) Drug+HPC 
 
Figure 6: DSC graph of cefuroxime axetil+HPMC K4 M+Ethyl cellulose+Eudragit RL 100+Hydroxy propyl 
cellulose 
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Evaluation of granules: 
Table 4:  Evaluation of granules 
 
 
EVALUATION OF TABLETS 
(A)Tablet thickness and size 
Size of formulations was found to be 9.5 to 11.5 mm. 
Thickness was found to be 5.0 to 5.4 mm for all the 
formulations. Every measurement was made in 
triplicate. 
 
Table 5: Tablet thickness and size 
 
(B)Tablet hardness 
Hardness of tablets of each formulation was measured 
and was found in the range of 3-5 kg/cm
2
. Each sample 
was analyzed in triplicate. 
(C)Friability 
Percentage weight loss of the tablets of each 
formulation was measured and was found to be less 
than 1% for all the formulations 
(E)Uniformity of weight 
Tablets from each batch showed uniformity of weight 
as per I. P. limits. Average weight of the tablet was 
found to be from 482 mg to 500 mg for all 
formulations
 
 
 
 
 
 
Table 6: Tablet hardness, friability and average weight 
 
(F) Drug content 
All tablets formulations showed 94.16 % to 100.86 % 
drug content. Tablets from each batch showed 
uniformity of content as per I.P limit 
(G)Buoyancy lag time 
Increasing the polymer concentration decreased the 
buoyancy lag time. Carbon dioxide which was liberated 
by the reaction of the sodium bicarbonate with the acidic 
environment of the gastric contents is entrapped in the 
gellified hydrocolloid. This produced an upward motion 
of the dosage form and maintains its buoyancy. 
Buoyancy lag time for all formulations was found to be 
less than 1 min. 
Table 7: Drug content 
Formulation Assay 
F1 94.16% 
F2 99.23% 
F3 100.86% 
F4 98.27% 
F5 96.80% 
F6 95.26% 
F7 99.86% 
 
 
Formulations 
Bulk Density 
(g/cc) 
Tapped Density 
(g/cc) 
Carr’s compressibility 
index 
Hausner’s 
ratio 
Angle of repose 
(degree) 
F1 0.211 0.380 0.444 1.800 35.68 
F2 0.221 0.387 0.428 1.751 42.30 
F3 0.214 0.378 0.433 1.766 35.68 
F4 0.229 0.370 0.381 1.615 35.68 
F5 0.22 0.367 0.400 1.668 41.34 
F6 0.218 0.390 0.441 1.788 35.68 
F7 0.221 0.385 0.462 1.859 40.69 
Formulations Thickness(mm) Diameter(mm) 
F1 5.0 10.5 
F2 5.2 11.2 
F3 5.2 9.5 
F4 5.3 11.5 
F5 5.4 10.9 
F6 5.4 11.2 
F7 5.3 11.5 
Formulations Hardness (kg/cm
2
) Friability (%) Average weight (mg) 
F1 3.8 0.21 482 
F2 4.2 0.43 497 
F3 3..6 0.28 500 
F4 4.3 0.30 489 
F5 3.8 0.47 493 
F6 4.6 0.49 490 
F7 4.3 0.51 487 
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(H) Buoyancy time 
Total floating time of all formulations is shown in Table  
Table 8: Buoyancy Lag Time 
 
 
               Table 9: Total floating time 
 
 
 
 
 
 
(I) Swelling Index of Tablet 
 
Figure 7: Swelling behavior of formulations F1 to F7. 
In vitro dissolution studies 
Table 10: Cumulative % drug released from floating tablet formulations of F1-F7 
Time 
(Hours) 
Cumulative %  release 
Formulation code 
 F1 F2 F3 F4 F5 F6 F7 
1 12.433 7.417 10.432 12.15056 15.15722 6.411111 4.102222 
2 13.10278 9.858333 14.390 17.21778 19.54111 13.04667 12.125 
3 14.575 15.41278 19.96944 22.61278 28.54889 16.41889 14.89222 
4 18.055 19.09778 26.67944 28.43722 33.80611 22.60944 24.07444 
5 22.05389 21.60278 32.42611 33.39333 36.69167 27.53389 31.90722 
6 24.47444 25.52111 36.80389 40.97611 42.49222 33.585 39.58278 
7 39.30778 30.96056 40.505 45.6 48.02389 37.06889 50.4 
8 50.62278 36.02944 47.42556 51.74833 57.985 43.17111 61.37611 
9 58.39944 42.92556 54.38333 58.82944 64.9 48.20611 70.11167 
10 63.31778 48.85889 57.67833 65.54833 71.75167 54.36778 77.89389 
11 66.16167 55.72389 60.59 69.30278 78.43944 58.36222 88.21722 
12 73.91944 64.52556 65.91611 74.57611 89.76222 64.07722 99.59556 
 
Drug release kinetics: 
Drug release profiles of the formulations were 
determined by fitting the dissolution data to zero order, 
first order and Higuchi equation. The equation for 
which the highest R
2
 was obtained was considered as 
the best fit release profile. The mechanism of drug 
release was determined by fitting the drug release data 
to Korsmeyer’s Peppas equation. The detail data 
treatment is presented in the next section. 
 
Drug Release Kinetics 
For all the formulation Korsmeyer’s Peppas exponent 
(n) was found to be greater than 0.5 (>0.5). This 
indicated that mechanism of drug release controlled 
from the  Cefuroxime Axetil floating tablet was based 
on diffusion as well as erosion phenomenon. The in 
vitro release kinetics exhibited a non-Fickian transport 
model. This kind of diffusion corresponds to a more 
predictable type of swelling-controlled system. 
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Table 11: Drug release kinetics of all formulation 
 
 
From the results shown in Table 11, we can conclude 
that, 
The overall order of release data of drug from implant, 
fitting in different mathematical model is as follows, 
1. F1 BATCH: 
 Zero order > First order > Korsmeyer Peppas > Higuchi 
2. F2 BATCH: 
 Zero order > Korsmeyer Peppas > Higuchi > First order 
3. F3 BATCH 
Zero order > Korsmeyer Peppas > Higuchi > First order 
4. F4 BATCH: 
Zero order > Korsmeyer Peppas > Higuchi > First order   
5. F5 BATCH:             
Zero order > Korsmeyer Peppas > Higuchi > First order   
6. F6 BATCH: 
  Zero order > Korsmeyer Peppas > Higuchi > First 
order   
7. F7 BATCH: 
 Zero order > Korsmeyer Peppas > Higuchi >  First 
order   
Release rate constant:  The release rate constant (k) of 
Zero order and First order for in vitro drug release of all 
formulations are given below in table 12 
Table 12: Zero order and first order release rate constants 
 
 
 
 
 
 
 
Release Profile Comparison: 
For the present study an attempt was made to prepare 
the GRDDS of Cefuroxime Axetil with 4 different 
polymers and their combinations. The study reveals that 
the drug release from formulations is depend upon the 
swelling, molecular weight and diffusion ability of 
polymers. From the observation it is concluded that 
formulation containing HPMC K4M and HPC i.e F1 & 
F4 shows the better release rate as it is used alone and 
having good swelling properties. 
The batches F1, F5, F6 and F7 were prepared using 
polymers HPMC K4M, HPMC K4M: Ethyl Cellulose, 
HPMC K4M:Eudragit RL100 and HPMC K4M: HPC 
respectively and Floating tablets were prepared for each 
batch. 
 The drug release rate decreased in the rank order; 
F7 > F5 > F1> F6 
This can probably be attributed to the different diffusion 
and swelling behavior of the combination of these 
polymers. With increasing molecular weight, the degree 
of entanglement of polymer chain increases. Thus, the 
mobility of the drug molecules in the fully swollen 
systems decreases. This leads to decreased drug 
diffusion coefficients and decreased drug release rate 
with increase molecular weight. It is stated that a faster 
and greater drug release was expected for reasons with 
the evolution of gas, the matrix would become more 
relaxed allowing water penetration and diffusion of drug 
might be easier.  
The drug release from F6 (HPMC K4M: Eudragit RL 
100) shows that, as HPMC K4M used in combination 
with eudragit RL 100, the drug release of formulation is 
decreases as compare to F1 (HPMC K4M). This is 
because of the swelling properties of polymers. 
From the above observation it is concluded that 
formulation F7 (HPMC-K: HPC) is the best formulation 
among all other 6 formulations because it is showing 
very controlled release of drug from Tablet formulations
 
Formulations Zero order First order Higuchi equation Korsmeyar’s Peppas 
 Equation of  
line 
Reg. 
coef 
Equation of 
line 
Reg. 
coef 
Equation of 
line 
Reg 
coef. 
Equation of 
line 
Reg. 
Coef. 
F1 0.101x-1.274 0.951 0.001x+ 0.998 0.950 3.246x-22.37 0.868 0.771x-0.429 0.893 
F2 0.082x-0.799 0.980 0.001x+0.773 0.900 2.680x-18.53 0.913 0.894x-0.822 0.982 
F3 0.087x+4.787 0.995 0.001x + 
0.987 
0.884 2.885x-15.11 0.976 0.767x-0.389 0.993 
F4 0.096x+5.656 0.998 0.001x+1.078 0.934 3.174x-15.92 0.961 0.693x-0.148 0.997 
F5 0.109x+6.448 0.990 0.001x+1.146 0.938 3.549x-17.40 0.940 0.671x-0.040 0.974 
F6 0.087 x 
+1.034 
0.998 0.001x+0.769 0.799 2.795x-18.84 0.973 1.018x-1.087 0.987 
F7 0.143x+7.727 0.992 0.002x+0.595 0.808 4.644x-38.68 0.933 1.374x-1.905 0.990 
Formulation Release Rate Constant 
 Zero Order First Order 
F1 0.232 0.002 
F2 0.191 0.002 
F3 0.200 0.002 
F4 0.214 0.002 
F5 0.251 0.002 
F6 0.200 0.002 
F7 0.329 0.004 
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Figure 8: Zero order plots of the in vitro drug release from the formulations F1-F7 
 
Figure 9: First order plots of the in vitro drug release from the formulations   F1-F7 
 
Figure: 10: Higuchi plots of the in vitro drug release from the formulations F1-F7 
 
Figure 11: Korsmeyers peppas plots of the in vitro drug release from the formulations   F1-F7 
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CONCLUSION: 
In the present study  gastro-retentive floating tablets of 
cefuroxime axetil were successfully prepared by wet 
granulation method using polymer HPMC K4M, EC, 
EUDRAGIT RL100 and HPC for sustained release of 
therapeutically active agent, cefuroxime axetil in upper 
part of gastro-intestinal tract in the form of floating 
tablet..  From the above observation it is concluded that 
formulation F7 (HPMC-K: HPC) is the best formulation 
among all other 6 formulations because it is showing 
very controlled release of drug from Tablet 
formulations. 
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